Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation

被引：17
作者：
Gillham C.M. [1 ]
Reynolds J. [1 ]
Hollywood D. [1 ]
机构：
[1] Academic Unit of Clinical and Molecular Oncology, St James's Hospital, Dublin
来源：
World Journal of Surgical Oncology | / 5卷 / 1期
关键词：
Epidermal Growth Factor Receptor; Standardize Uptake Value; Pathological Response; Oesophageal Cancer; Tumour Regression Grade;
D O I：
10.1186/1477-7819-5-97
中图分类号：
学科分类号：
摘要：
Background: A complete pathological response to neo-adjuvant chemo-radiation for oesophageal cancer is associated with favourable survival. However, such a benefit is seen in the minority. If one could identify, at diagnosis, those patients who were unlikely to respond unnecessary toxicity could be avoided and alternative treatment can be considered. The aim of this review was to highlight predictive markers currently assessed and evaluate their clinical utility. Methods: A systematic search of Pubmed and Google Scholar was performed using the following keywords; "neo-adjuvant", "oesophageal", "trimodality", "chemotherapy", "radiotherapy", "chemoradiation" and "predict". The original manuscripts were sourced for further articles of relevance. Results: Conventional indices including tumour stage and grade seem unable to predict histological response. Immuno-histochemical markers have been extensively studied, but none has made its way into routine clinical practice. Global gene expression from fresh pre-treatment tissue using cDNA microarray has only recently been assessed, but shows considerable promise. Molecular imaging using FDG-PET seems to be able to predict response after neo-adjuvant chemoradiation has finished, but there is a paucity of data when such imaging is performed earlier. Conclusion: Currently there are no clinically useful predictors of response based on standard pathological assessment and immunohistochemistry. Genomics, proteomics and molecular imaging may hold promise. © 2007 Gillham et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 95 条
[1]  
MINDACT, (Microarray In Node Negative Disease May Avoid ChemoTherapy) (EORTC Protocol 10041 - BIG 3-04), (2007)
[2]  
Parkin D.M., International variation, Oncogene, 23, pp. 6329-6340, (2004)
[3]  
Iizuka T., Isono K., Kakegawa T., Watanabe H., Parameters linked to ten-year survival in Japan of resected esophageal carcinoma. Japanese Committee for Registration of Esophageal Carcinoma Cases, Chest, 96, pp. 1005-1011, (1989)
[4]  
Daly J.M., Karnell L.H., Menck H.R., National cancer database report on esophageal carcinoma, Cancer, 78, pp. 1820-1828, (1996)
[5]  
Crew K.D., Neugut A.I., Epidemiology of upper gastrointestinal malignancies, Semin Oncol, 31, pp. 450-464, (2004)
[6]  
Enzinger P.C., Mayer R.J., Esophageal Cancer, N Engl J Med, 349, pp. 2241-2252, (2003)
[7]  
Altorki N., Kent M., Ferrara R.N., Port J., Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus, Ann Surg, 236, pp. 177-183, (2002)
[8]  
Lerut T., Coosemans W., De Leyn P., Deneffe G., Topal B., Van de Ven C., Van Raemdonck D., Reflections on 3-field lymphadenectomy in carcinoma of the esophagus and gastroesophageal junction, Hepato-Gastroenterology, 46, pp. 717-725, (1999)
[9]  
Suntharalingam M., Moughan J., Coia L.R., Krasna M.J., Kachnic L., Haller D.G., Willett C.G., John M.J., Minsky B.D., Owen J.B., The national practice for patients receiving radiation therapy for carcinoma of the esophagus: Results of the 1996-1999 Patterns of Care Study, Cancer, 85, pp. 2499-2505, (1999)
[10]  
Geh J.I., Crellin A.M., Glynne-Jones R., Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer, Br J Surg, 88, pp. 338-356, (2001)
12345678910